Back to top
more

NuVasive, Inc. (NUVA)

(Delayed Data from NSDQ)

$62.96 USD

62.96
567,418

+0.74 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $62.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ResMed (RMD) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

ResMed (RMD) gains from promising financial results in the fourth quarter of fiscal 2019.

Here's Why You Should Hold Onto Insulet (PODD) Stock for Now

by Zacks Equity Research

Investor confidence continues to be high on Insulet's (PODD) solid prospects.

Boston Scientific Rides on New Products Amid Dull Pacer Sales

by Zacks Equity Research

Within MedSurg, Boston Scientific (BSX) is on track for the year-end launch of Exalt-D Single-Use Duodenoscope, which is used in ERCP procedures.

    Baxter (BAX) Hits 52-Week High, Can the Run Continue?

    by Zacks Equity Research

    Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

    Canopy Growth Set to Acquire Beckley Canopy Therapeutics

    by Zacks Equity Research

    With the Beckley Canopy Therapeutics acquisition, Canopy Growth's (CGC) research and development endeavors would be expanding worldwide, thereby making the company a global pioneer in cannabinoid research.

    National Vision (EYE) Q2 Earnings Lag Estimates, Margins Down

    by Zacks Equity Research

    National Vision's (EYE) Military brand registers robust growth while other brands fail to impress.

    Haemonetics (HAE) Beats on Q1 Earnings, Raises '19 EPS View

    by Zacks Equity Research

    Haemonetics (HAE) Q1 performance by all business sections has been impressive, except for BloodCenter.

    NUVA vs. RMD: Which Stock Is the Better Value Option?

    by Zacks Equity Research

    NUVA vs. RMD: Which Stock Is the Better Value Option?

    Will NuVasive Continue to Surge Higher?

    by Zacks Equity Research

    As of late, it has definitely been a great time to be an investor NuVasive.

    NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q2

    by Zacks Equity Research

    NuVasive (NUVA) witnesses balanced revenue growth across majority of key operating segments.

    NuVasive (NUVA) Tops Q2 Earnings and Revenue Estimates

    by Zacks Equity Research

    NuVasive (NUVA) delivered earnings and revenue surprises of 12.50% and 0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

    Nalak Das headshot

    Buy 6 Top Stocks Set to Beat on Earnings in Q2 Today

    by Nalak Das

    Second-quarter 2019 earnings expectations have improved this month. In spite of a prolonged trade conflict with China, we do not see a broad-based decline in guidance by U.S. corporates.

    Why the Earnings Surprise Streak Could Continue for NuVasive (NUVA)

    by Zacks Equity Research

    NuVasive (NUVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    NuVasive (NUVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    by Zacks Equity Research

    NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Henry Schein Closes Acquisition of Elite Computer Italia

    by Zacks Equity Research

    The Elite Computer acquisition marks Henry Schein's (HSIC) foray into the Italian dental practice management software market.

    NextGen Inks Deal With Appriss Health, Boosts EHR System

    by Zacks Equity Research

    NextGen (NXGN) integrates Appriss Health prescription monitoring and tracking analytics into NextGen Office that is likely to enhance the former's EHR system.

    Intuitive Surgical to Boost da Vinci Platform With Buyout

    by Zacks Equity Research

    Intuitive Surgical's (ISRG) acquisition of Scholly Fiberoptic's robotic endoscope business to likely boost the acquirer's da Vinci Surgical system.

    Chemed's Roto-Rooter & VITAS Robust, Acuity Mix Shift Weak

    by Zacks Equity Research

    Chemed's (CHE) VITAS shows higher adoption via an expanded average daily census. Also, the Roto-Rooter's business grows on the back of strong core plumbing and drain cleaning service segments.

    Masimo (MASI) Hits a 52-Week High on Solid Growth Drivers

    by Zacks Equity Research

    Masimo (MASI) gains from expansion of product portfolio and recent regulatory approvals.

    Abbott MitraClip G4 Gets FDA Nod, Valve Repair Options Expand

    by Zacks Equity Research

    The FDA approval for MitraClip G4 is expected to enhance Abbott's (ABT) cardiac treatment portfolio.

    ABT or BIO: Which Stock Has Better Potential Right Now?

    by Zacks Equity Research

    Abbott (ABT) scores higher than Bio-Rad (BIO) in terms of valuation and one-year price performance.

    Here's Why You Should Hold Onto Neogen (NEOG) Stock Now

    by Zacks Equity Research

    Investors' trust continues to be high in Neogen (NEO), thanks to strength in its Food Safety and Genomic businesses.

    TFX or STE: Which is a Better Investment Pick Right Now?

    by Zacks Equity Research

    STERIS (STE) scores higher than Teleflex (TFX) when it comes to valuation and one-year price performance.

    NuVasive (NUVA) Launches Pulse Integrated Technology Platform

    by Zacks Equity Research

    The launch of this system is in sync with NuVasive's (NUVA) endeavor to deliver end-to-end solutions that offer predictable clinical and economic outcomes in spine surgery.

    NuVasive Grows on Strong Product Adoption Amid Pricing Woe

    by Zacks Equity Research

    Introduction of multiple products within the Spinal Hardware, balanced revenue growth across key operating segments and robust international sales perk up NuVasive's (NUVA) share price.